Evotec signed a high-throughput screening agreement with Active Biotech. The company is tasked with identifing and validating novel hits against an Active Biotech target involved in immune disorders and cancer.
Screening will focus on Evotec’s own small molecule Lead Discovery Library. The firm will leverage its high-throughput screening and surface plasmon resonance screening capabilities.
“We are impressed by the excellent quality of Evotec’s Lead Discovery Library, which we believe will enable us to generate high-quality hits, ensuring a smooth transition to medicinal chemistry activities,” comments Dorthe da Graça Trhige, Active Biotech’s director of development. “Importantly, the hits identified in the HTS will complement the ongoing lead optimization of compounds identified in house.”